ERBB2 and breast cancer: When neoadjuvant chemotherapy is planned for invasive, operable HER2-positive breast cancer, adding trastuzumab to chemotherapy is strongly recommended, because chemotherapy plus trastuzumab is shown to increase pathological complete response rate compared with chemotherapy alone for invasive, operable HER2-positive breast cancer (SoR: 1, SoE: moderate).